Latest Novavax Inc (NVAX) Headlines Looking for
Post# of 317
Posted On: 03/13/2014 12:27:33 AM
Latest Novavax Inc (NVAX) Headlines
Looking for Bargain Biotechs? Consider Small-Cap Vaccine Makers
George Budwell, The Motley Fool - Motley Fool - Wed Mar 12, 5:30PM CDT
Growth and value are two words that have completely fallen out of the biotech lexicon of late. The adjectives 'bubble' and 'expensive' have instead taken their place, when investors talk biotech. And with the average biotech price to earnings ratio...
Pre-Market Equity Coverage - Most Active: Comcast, America Movil, Novavax, and Real Goods Solar
PR Newswire - Wed Mar 12, 11:41AM CDT
The trading session on Tuesday, March 11, 2014 ended on a lower note as the Dow Jones Industrial Average finished at 16,351.25, down 0.41% and the NASDAQ Composite closed at 4,307.19, down 0.63%. The S&P 500 finished the session 0.51% lower at 1,867.63. The losses were broad based as nine of ten sectors ended the session in negative. Investor-Edge.com looks at some of the equities which were most active during the session. These include Comcast Corp. (NASDAQ:CMCSA), America Movil S.A.B. de C.V. (NYSE:AMX), Novavax Inc. (NASDAQ:NVAX), and Real Goods Solar Inc. (NASDAQ:RGSE). Free research on these four companies can be accessed at:
Nanotechnology Drug Delivery Market in the US 2012-2016 with Celgene Corp., Novartis AG and SkyePharma plc. Dominating
M2 - Wed Mar 12, 11:14AM CDT
Research and Markets (http://www.researchandmarkets.com/research/3r7bw6/nanotechnology) has announced the addition of the "Nanotechnology Drug Delivery Market in the US 2012-2016" report to their offering. The analysts forecast the Nanotechnology Drug Delivery market in the US to grow at a CAGR of 84.79 percent over the period 2012-2016. One of the key factors contributing to this market growth is the low R and D cost. The Nanotechnology Drug Delivery market in the US has also been witnessing the trend of emergence of personalized medicines. However, the increasing safety concerns could pose a challenge to the growth of this market. Key vendors dominating this space include Alkermes plc., Celgene Corp., Novartis AG and SkyePharma plc. Other vendors mentioned in the report are Merck and Co. Inc., Pfizer Inc., AlphaRx Inc., Amgen, Inc., Angiotech Pharmaceuticals, Inc., Biophan Technologies, Inc., Calando Pharmaceuticals, Inc., Cephalon, Inc., Cerulean Pharma, Inc, Copernicus Therapeutics, Inc., CritiTech, Inc., CytImmune Sciences, Inc., Elan Corporation, plc, Debiotech SA, F. Hoffmann-La Roche Ltd, Nano Interface Technology, Inc, Spherics, Inc., Spectrum Pharmaceuticals, Inc., SoluBest Ltd., Sigma-Tau Pharmaceuticals, Inc., PharmaNova Inc. Particle Sciences, Inc., Novavax, Inc., Nanotherapeutics, Inc., NanoSight Ltd., NanoCarrier Co. Ltd., NanoBioMagnetics, Inc., Nano Interface Technology, Inc, Merck Sharp and Dohme Corp., Kuecept Ltd., Izon Science Ltd. Commenting on the report, an analyst from the Healthcare team said: 'Over the years, the research activities in healthcare have changed significantly. There has been a paradigm shift away from blockbusters drugs to a more personalized medicine approach. The focus is being placed increasingly on formulating drugs based on the individual's unique genome and immune response. Personalized medicines have gained significant popularity because they enable the medical profession to provide customized treatment to patients. A customized treatment is based on the genetic as well as medical profile of a patient. Increasing knowledge about the molecular causes of diseases is increasing the demand for more targeted and effective nanotechnology-enabled drug delivery therapies.' For more information visit http://www.researchandmarkets.com/research/3r...technology About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Why Novavax, Inc. Shares Popped Today
Brian Pacampara, The Motley Fool - Motley Fool - Tue Mar 11, 11:19AM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of biopharmaceutical company Novavax climbed...
Novavax Reports Fourth-Quarter and Year-End 2013 Financial Results and Initiation of Phase 1/2 Clinical Trial of Its H7N9 Avian Influenza VLP Vaccine Candidate With Matrix-M(TM)
Thomson Reuters ONE - Mon Mar 10, 3:32PM CDT
GAITHERSBURG, Md., March 10, 2014 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants, today reported its financial results for the fourth quarter and year ended December 31, 2013 and announced the initiation of a Phase 1/2 clinical trial of its H7N9 avian influenza VLP vaccine candidate with its proprietary Matrix-M adjuvant. The trial is enrolling 610 healthy subjects to evaluate the safety and immunogenicity of this vaccine and adjuvant.
Novavax Appoints John J. Trizzino as Senior Vice President, Commercial Operations
GlobeNewswire - Mon Mar 10, 9:02AM CDT
Novavax, Inc. (Nasdaq:NVAX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants, today announced the appointment of John J. Trizzino to the position of Senior Vice President, Commercial Operations, effective March 10, 2014. Mr. Trizzino will be responsible for developing and implementing the commercialization strategy in support of the company's product candidates, including its RSV F, quadrivalent seasonal and pandemic influenza vaccine candidates.
3 Predictions for the New Week
Rick Munarriz, The Motley Fool - Motley Fool - Sun Mar 09, 2:00PM CDT
I went out on a limb last week , and now it's time to see how that decision played out. I predicted that RadioShack would post a wider loss than expected. The struggling small-box retailer of wireless products and other consumer electronics...
New Appointments, Contract Extensions, Share Price Movements, Conference Schedules, and Closing of Public Offerings - Analyst Notes on Ariad, Novavax, Fonar, bluebird, and Cara
PR Newswire - Wed Mar 05, 6:24AM CST
Today, Analysts Review released its analysts' notes regarding Ariad Pharmaceuticals Inc. (NASDAQ: ARIA), Novavax, Inc. (NASDAQ: NVAX), Fonar Corp. (NASDAQ: FONR), bluebird bio, Inc. (NASDAQ: BLUE), and Cara Therapeutics Inc. (NASDAQ: CARA). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register
5 of Last Week's Biggest Winners
Rick Munarriz, The Motley Fool - Motley Fool - Sun Mar 02, 10:15AM CST
What's better than momentum? Mo' momentum. Let's take a closer look at five of this past week's biggest scorchers. Company Feb. 28 Weekly Gain J.C. Penney $7.28 29% Kandi Technologies ...
Novavax Announces Extension of Contract for Advanced Development of Recombinant Influenza Products and Pandemic Preparedness With HHS-BARDA
Thomson Reuters ONE - Thu Feb 27, 3:17PM CST
This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
Novavax to Report Fourth Quarter and Year-End 2013 Financial Results on March 10, 2014
Thomson Reuters ONE - Wed Feb 19, 3:47PM CST
ROCKVILLE, Md., Feb. 19, 2014 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX) announced today that it will host a conference call and webcast to report its fourth quarter and year-end 2013 financial results on Monday, March 10, 2014, at 4:30 p.m. ET.
5 Biotech Stocks to Trade in February
at The Street - Mon Feb 10, 1:15PM CST
These biotech stocks scheduled to present at the BIO CEO conference could be poised for sharp spikes higher.
Insider Trading Alert - BSFT, AMBA, GOOG, ADT And NVAX Traded By Insiders
at The Street - Wed Feb 05, 10:15AM CST
Stocks with insider trader activity include BSFT, AMBA, GOOG, ADT and NVAX
Novavax Has Returned 64.3% Since SmarTrend Recommendation (NVAX)
Comtex SmarTrend(R) - Tue Feb 04, 4:57PM CST
SmarTrend identified an Uptrend for Novavax (NASDAQ:NVAX) on November 21st, 2013 at $3.28. In approximately 3 months, Novavax has returned 64.33% as of today's recent price of $5.39.
Trade-Ideas: Novavax (NVAX) Is Today's "Dead Cat Bounce" Stock
at The Street - Mon Feb 03, 8:46AM CST
Trade-Ideas LLC identified Novavax (NVAX) as a "dead cat bounce" (down big yesterday but up big today) candidate
Foresight Research Says the North American International Auto Show is a Shopping Paradise for Attendees
GlobeNewswire - Thu Jan 30, 3:07PM CST
Foresight Research, the leader in auto show research and insights, released initial results from the North American International Auto Show today revealing that show attendees were actively shopping for cars and trucks - and making up their minds about car purchases as a result of their visit to the show. The study, in its third year, reaches out to over 1,000 households in the Detroit area in the days following the auto show. With a sample of over 200 people who actually attended the show to ensure reliable measurement.
Looking for Bargain Biotechs? Consider Small-Cap Vaccine Makers
George Budwell, The Motley Fool - Motley Fool - Wed Mar 12, 5:30PM CDT
Growth and value are two words that have completely fallen out of the biotech lexicon of late. The adjectives 'bubble' and 'expensive' have instead taken their place, when investors talk biotech. And with the average biotech price to earnings ratio...
Pre-Market Equity Coverage - Most Active: Comcast, America Movil, Novavax, and Real Goods Solar
PR Newswire - Wed Mar 12, 11:41AM CDT
The trading session on Tuesday, March 11, 2014 ended on a lower note as the Dow Jones Industrial Average finished at 16,351.25, down 0.41% and the NASDAQ Composite closed at 4,307.19, down 0.63%. The S&P 500 finished the session 0.51% lower at 1,867.63. The losses were broad based as nine of ten sectors ended the session in negative. Investor-Edge.com looks at some of the equities which were most active during the session. These include Comcast Corp. (NASDAQ:CMCSA), America Movil S.A.B. de C.V. (NYSE:AMX), Novavax Inc. (NASDAQ:NVAX), and Real Goods Solar Inc. (NASDAQ:RGSE). Free research on these four companies can be accessed at:
Nanotechnology Drug Delivery Market in the US 2012-2016 with Celgene Corp., Novartis AG and SkyePharma plc. Dominating
M2 - Wed Mar 12, 11:14AM CDT
Research and Markets (http://www.researchandmarkets.com/research/3r7bw6/nanotechnology) has announced the addition of the "Nanotechnology Drug Delivery Market in the US 2012-2016" report to their offering. The analysts forecast the Nanotechnology Drug Delivery market in the US to grow at a CAGR of 84.79 percent over the period 2012-2016. One of the key factors contributing to this market growth is the low R and D cost. The Nanotechnology Drug Delivery market in the US has also been witnessing the trend of emergence of personalized medicines. However, the increasing safety concerns could pose a challenge to the growth of this market. Key vendors dominating this space include Alkermes plc., Celgene Corp., Novartis AG and SkyePharma plc. Other vendors mentioned in the report are Merck and Co. Inc., Pfizer Inc., AlphaRx Inc., Amgen, Inc., Angiotech Pharmaceuticals, Inc., Biophan Technologies, Inc., Calando Pharmaceuticals, Inc., Cephalon, Inc., Cerulean Pharma, Inc, Copernicus Therapeutics, Inc., CritiTech, Inc., CytImmune Sciences, Inc., Elan Corporation, plc, Debiotech SA, F. Hoffmann-La Roche Ltd, Nano Interface Technology, Inc, Spherics, Inc., Spectrum Pharmaceuticals, Inc., SoluBest Ltd., Sigma-Tau Pharmaceuticals, Inc., PharmaNova Inc. Particle Sciences, Inc., Novavax, Inc., Nanotherapeutics, Inc., NanoSight Ltd., NanoCarrier Co. Ltd., NanoBioMagnetics, Inc., Nano Interface Technology, Inc, Merck Sharp and Dohme Corp., Kuecept Ltd., Izon Science Ltd. Commenting on the report, an analyst from the Healthcare team said: 'Over the years, the research activities in healthcare have changed significantly. There has been a paradigm shift away from blockbusters drugs to a more personalized medicine approach. The focus is being placed increasingly on formulating drugs based on the individual's unique genome and immune response. Personalized medicines have gained significant popularity because they enable the medical profession to provide customized treatment to patients. A customized treatment is based on the genetic as well as medical profile of a patient. Increasing knowledge about the molecular causes of diseases is increasing the demand for more targeted and effective nanotechnology-enabled drug delivery therapies.' For more information visit http://www.researchandmarkets.com/research/3r...technology About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Why Novavax, Inc. Shares Popped Today
Brian Pacampara, The Motley Fool - Motley Fool - Tue Mar 11, 11:19AM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of biopharmaceutical company Novavax climbed...
Novavax Reports Fourth-Quarter and Year-End 2013 Financial Results and Initiation of Phase 1/2 Clinical Trial of Its H7N9 Avian Influenza VLP Vaccine Candidate With Matrix-M(TM)
Thomson Reuters ONE - Mon Mar 10, 3:32PM CDT
GAITHERSBURG, Md., March 10, 2014 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants, today reported its financial results for the fourth quarter and year ended December 31, 2013 and announced the initiation of a Phase 1/2 clinical trial of its H7N9 avian influenza VLP vaccine candidate with its proprietary Matrix-M adjuvant. The trial is enrolling 610 healthy subjects to evaluate the safety and immunogenicity of this vaccine and adjuvant.
Novavax Appoints John J. Trizzino as Senior Vice President, Commercial Operations
GlobeNewswire - Mon Mar 10, 9:02AM CDT
Novavax, Inc. (Nasdaq:NVAX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants, today announced the appointment of John J. Trizzino to the position of Senior Vice President, Commercial Operations, effective March 10, 2014. Mr. Trizzino will be responsible for developing and implementing the commercialization strategy in support of the company's product candidates, including its RSV F, quadrivalent seasonal and pandemic influenza vaccine candidates.
3 Predictions for the New Week
Rick Munarriz, The Motley Fool - Motley Fool - Sun Mar 09, 2:00PM CDT
I went out on a limb last week , and now it's time to see how that decision played out. I predicted that RadioShack would post a wider loss than expected. The struggling small-box retailer of wireless products and other consumer electronics...
New Appointments, Contract Extensions, Share Price Movements, Conference Schedules, and Closing of Public Offerings - Analyst Notes on Ariad, Novavax, Fonar, bluebird, and Cara
PR Newswire - Wed Mar 05, 6:24AM CST
Today, Analysts Review released its analysts' notes regarding Ariad Pharmaceuticals Inc. (NASDAQ: ARIA), Novavax, Inc. (NASDAQ: NVAX), Fonar Corp. (NASDAQ: FONR), bluebird bio, Inc. (NASDAQ: BLUE), and Cara Therapeutics Inc. (NASDAQ: CARA). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register
5 of Last Week's Biggest Winners
Rick Munarriz, The Motley Fool - Motley Fool - Sun Mar 02, 10:15AM CST
What's better than momentum? Mo' momentum. Let's take a closer look at five of this past week's biggest scorchers. Company Feb. 28 Weekly Gain J.C. Penney $7.28 29% Kandi Technologies ...
Novavax Announces Extension of Contract for Advanced Development of Recombinant Influenza Products and Pandemic Preparedness With HHS-BARDA
Thomson Reuters ONE - Thu Feb 27, 3:17PM CST
This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
Novavax to Report Fourth Quarter and Year-End 2013 Financial Results on March 10, 2014
Thomson Reuters ONE - Wed Feb 19, 3:47PM CST
ROCKVILLE, Md., Feb. 19, 2014 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX) announced today that it will host a conference call and webcast to report its fourth quarter and year-end 2013 financial results on Monday, March 10, 2014, at 4:30 p.m. ET.
5 Biotech Stocks to Trade in February
at The Street - Mon Feb 10, 1:15PM CST
These biotech stocks scheduled to present at the BIO CEO conference could be poised for sharp spikes higher.
Insider Trading Alert - BSFT, AMBA, GOOG, ADT And NVAX Traded By Insiders
at The Street - Wed Feb 05, 10:15AM CST
Stocks with insider trader activity include BSFT, AMBA, GOOG, ADT and NVAX
Novavax Has Returned 64.3% Since SmarTrend Recommendation (NVAX)
Comtex SmarTrend(R) - Tue Feb 04, 4:57PM CST
SmarTrend identified an Uptrend for Novavax (NASDAQ:NVAX) on November 21st, 2013 at $3.28. In approximately 3 months, Novavax has returned 64.33% as of today's recent price of $5.39.
Trade-Ideas: Novavax (NVAX) Is Today's "Dead Cat Bounce" Stock
at The Street - Mon Feb 03, 8:46AM CST
Trade-Ideas LLC identified Novavax (NVAX) as a "dead cat bounce" (down big yesterday but up big today) candidate
Foresight Research Says the North American International Auto Show is a Shopping Paradise for Attendees
GlobeNewswire - Thu Jan 30, 3:07PM CST
Foresight Research, the leader in auto show research and insights, released initial results from the North American International Auto Show today revealing that show attendees were actively shopping for cars and trucks - and making up their minds about car purchases as a result of their visit to the show. The study, in its third year, reaches out to over 1,000 households in the Detroit area in the days following the auto show. With a sample of over 200 people who actually attended the show to ensure reliable measurement.
(0)
(0)Novavax Inc. (NVAX) Stock Research Links
Scroll down for more posts ▼